CJC-1295 No DAC / Ipamorelin is a dual-peptide research formulation combining a synthetic GHRH analog with a selective growth hormone secretagogue. The two compounds interact with separate receptor systems associated with growth hormone signaling, providing researchers with a multi-pathway model for studying pituitary and neuroendocrine communication.

CJC-1295 No DAC is derived from growth hormone-releasing hormone and interacts with GHRH receptors within the anterior pituitary. Without the Drug Affinity Complex modification, the peptide has a shorter duration of activity and has been investigated in research involving transient GHRH signaling and pulsatile growth hormone release.

Ipamorelin is a synthetic pentapeptide studied for its interaction with the growth hormone secretagogue receptor (GHS-R). Laboratory investigations have examined its receptor activity and relationship with growth hormone-related signaling mechanisms.

This formulation combines 5mg CJC-1295 No DAC and 5mg Ipamorelin and is typically supplied as a white, lyophilized powder for controlled laboratory investigation involving GHRH and GHS-R signaling, pituitary biology, and related growth hormone pathways.